Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flexible pricing could work in Europe

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline recently published its corporate responsibility report, which shone a spotlight on a pricing system that promotes access to affordable medicines, whilst ensuring a healthy return for reinvestment in R&D. The flexible pricing mechanism has been employed successfully by the company to increase access to medicines in middle income countries (MICs), such as Brazil, China, Thailand, India and Indonesia. The question many are asking is whether such a system could be brought to Europe and if so, would it be valuable?

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel